This is an aggregated industry headline. Read the full story at FiercePharma →
In a first, Otsuka's Voyxact stabilizes IgAN patients' kidney function decline to normal levels
In a milestone for IgA nephropathy, Otsuka's Voyxact has shown for the first time in a phase 3 trial that a drug can stabilize patients' kidney function decline to the normal rate seen in healthy adults.
By FiercePharma
· Aug 4, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
As Amgen's flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive car…
The WeekFierceBiotech ↗
Contract research organization Icon announced a multi-year collaboration with Anthropic this week to bring Cla…
The WeekBriefing
A new analysis challenged a controversial federal-law provision that exempts certain orphan drugs from Medicar…